Abstract
Abstract. In the development of new psychiatric drugs and the exploration of their efficacy, behavioral testing in mice has always shown to be an inevitable procedure. By studying the behavior of mice, diverse pathophysiological processes leading to depression, anxiety, and sickness behavior have been revealed. Moreover, laboratory research in animals increased at least the knowledge about the involvement of a multitude of genes in anxiety and depression. However, multiple new possibilities to study human behavior have been developed recently and improved and enable a direct acquisition of human epigenetic, imaging, and neurotransmission data on psychiatric pathologies. In human beings, the high influence of environmental and resilience factors gained scientific importance during the last years as the search for key genes in the development of affective and anxiety disorders has not been successful. However, environmental influences in human beings themselves might be better understood and controllable than in mice, where environmental influences might be as complex and subtle. The increasing possibilities in clinical research and the knowledge about the complexity of environmental influences and interferences in animal trials, which had been underestimated yet, question more and more to what extent findings from laboratory animal research translate to human conditions. However, new developments in behavioral testing of mice involve the animals’ welfare and show that housing conditions of laboratory mice can be markedly improved without affecting the standardization of results.
References
(2014). Excess risk of chronic physical conditions associated with depression and anxiety. Biomedcentral Psychiatry, 14, 10.
(2013). Animal models of anxiety disorders and stress. Revista Brasileira de Psiquiatria, 35, S101–S111.
(2012). The tail suspension test. Journal of Visualized Experiments, 59, 3769.
(2004). Psychobiological mechanisms of resilience and vulnerability: Implications for successful adaptation to extreme stress. The American Journal of Psychiatry, 161, 195–216.
(2004). Festina lente: Late-night thoughts on high-throughput screening of mouse behavior. Nature Neuroscience, 7, 1175–1179.
(1980). Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacology Biochemistry and Behavior, 13, 167–170.
(2005). The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neuroscience & Biobehavioral Reviews, 29, 571–625.
(1999). Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. The Journal of Neuroscience, 19, 9550–9556.
(2003). Depression as a risk factor for Alzheimer disease: The MIRAGE study. Archives of Neurology, 60, 753–759.
(1997). Risk assessment behaviour: Evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. Pharmacology Biochemistry and Behavior, 57, 817–827.
(1934). Emotional behavior of the rat. Defecation and urination as measures of the individual differences in emotionality. Journal of Comparative Psychology, 18, 385–403.
(1984). Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of “fear”-motivated behaviour. Naunyn Schmiedebergs Archives of Pharmacology, 327, 1–5.
(2000). Major depression is a risk factor for seizures in older adults. Annals of Neurology, 47, 246–249.
(2007). What’s wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression. Behavioural Brain Research, 179, 1–18.
(2001). 8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. Psychopharmacology (Berl), 153, 365–372.
(2010). Linking molecules to mood: New insight into the biology of depression. The American Journal of Psychiatry, 167, 1305–1320.
(2013). Molecular mechanisms of depression: Perspectives on new treatment strategies. Cellular Physiology and Biochemistry, 31, 761–777.
(2006). Reduced locomotion in the serum and glucocorticoid inducible kinase 3 knock out mouse. Behavioural Brain Research, 167, 75–86.
(2013). Akt2 deficiency is associated with anxiety and depressive behaviour in mice. Cellular Physiology and Biochemistry, 32, 766–777.
(2003). Impaired explorative behavior and neophobia in genetically modified mice lacking or overexpressing the extracellular serine protease inhibitor neuroserpin. Molecular and Cellular Neuroscience, 23, 473–494.
(1984). Learned helplessness and animal models of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 8, 435–446.
(2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med, 3(11), e442.
(1958). The relation between fear induced by novel stimulation and exploratory behaviour. Journal of Comparative and Physiological Psychology, 48, 254–260.
(2009). Depression and type 2 diabetes over the lifespan: A meta-analysis. Response to Mezuk et al. Diabetes Care, 32, 56–57.
(2000). Restraint-induced hypoactivity in an elevated plus-maze. Brazilian Journal of Medical and Biological Research, 33, 79–83.
(1986). Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat. Pharmacology Biochemistry and Behavior, 24, 525–529.
(1998). Chronically depressed mood and cancer risk in older persons. Journal of the National Cancer Institute, 90, 1888–1893.
(2002). Harnessing the mouse to unravel the genetics of human disease. Genes, Brain and Behavior, 1, 14–26.
(2003). Antipanic-like effect of serotonin reuptake inhibitors in the elevated T-maze. Behavioural Brain Research, 147, 185–192.
(2000). Animal models of depression: Utility for transgenic research. Reviews Neuroscience, 11, 53–58.
(1977). Depression: A new animal model sensitive to antidepressant treatments. Nature, 266, 730–732.
(2006). Transgenic mice overexpressing glycogen synthase kinase 3beta: A putative model of hyperactivity and mania. The Journal of Neuroscience, 26, 9022–9029.
(2003). Effect of depression on stroke morbidity and mortality. Canadian Journal of Psychiatry, 48, 250–257.
(2011). Animal models for depression and the mismatch hypothesis of disease. Psychoneuroendocrinology, 36, 330–338.
(2007). Depression-anxiety relationships with chronic physical conditions: Results from the World Mental Health Surveys. Journal of Affective Disorders, 103, 113–120.
(1985). The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology (Berl), 85, 367–370.
(2000). Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety. Pharmacology Biochemistry and Behavior, 65, 571–576.
(2007). Depression and the risk for cardiovascular diseases: Systematic review and meta-analysis. International Journal of Geriatric Psychiatry, 22, 613–626.
(2014). Spontaneous behavior in the social homecage discriminates strains, lesions and mutations in mice. Journal of Neuroscience Methods, 234, 26–37.
(2013). Learned helplessness: Unique features and translational value of a cognitive depression model. Cell and Tissue Research, 354, 171–178.
(2006). Stability of inbred mouse strain differences in behavior and brain size between laboratories and across decades. Proceedings of the National Academy of Sciences of the United States of America, 103, 16364–16369.
(2006). The exploratory behavior of rats in an open environment optimizes security. Behavioural Brain Research, 171, 230–239.
(2004). Laboratory animal welfare: Cage enrichment and mouse behaviour. Nature, 432, 821–822.
